Eli Lilly (NYSE:LLY) announces positive results from a China-based Phase 3 clinical trial, ORIENT-11, evaluating the combination of Tyvyt (sintilimab injection), Alimta (pemetrexed) and platinum-based chemo for the first-line treatment of advanced/recurrent nonsquamous non-small cell lung cancer (nsqNSCLC), without sensitive EGFR mutation or ALK rearrangement.
The study met the primary endpoint of progression-free survival based on an interim analysis by the Independent Data Monitoring Committee.
No new safety signals were observed.
The trial is being conducted by sentilimab development partner Innovent Biologics. A marketing application in China is next up.
Additional data will be presented at an upcoming medical conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.